FGFeng Guo

Feng Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Feng Guo has a total of 49 co-authors. Here are the top co-authors by number of shared publications:

  • Guijun Qin

    Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

    2 shared publications
  • Yi Song

    Department of Endocrinology and Metabolism, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Tianjian Laboratory of Advanced Biomedical Sciences, Zhengzhou 450001, China

    2 shared publications
  • Chunhui Lyu

    The First Affiliated Hospital of Zhengzhou University

    1 shared publication
  • Congcong Wang

    The First Affiliated Hospital of Zhengzhou University

    1 shared publication
  • Fangfang Hu

    Department of Neurology the First Affiliated Hospital of Xi'an Jiaotong University Xi'an Shaanxi People's Republic of China

    1 shared publication
  • Fangyi Wei

    Department of Endocrinology and Metabolism, First Affiliated Hospital of Zhengzhou University, NO.1 Jianshe East Rd., Zhengzhou, Henan 450052, China; Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, China

    1 shared publication

Latest Publications

  • Compound Danshen Dripping Pills moderate intestinal flora and the TLR4/MyD88/NF-κB signaling pathway in alleviating cognitive dysfunction in type 2 diabetic KK-Ay mice

    by Xunjie Fan, Yuanyuan Zhang, Yi Song, Yanyan Zhao, Yanan Xu, Feng Guo, Mingwei Shao, Xiaojun Ma, Wei Zhang, Fangyi Wei, et al.


  • Open Access

    High Expression of ECM1 At Diagnosis Predicated Poor Prognosis in Adult B-Cell Acute Lymphoblastic Leukemia

    by Weimin Wang, Feifei Wu, Fei Wang, Congcong Wang, Chunhui Lyu, Lijie Han, Silin Gan, Ping Ma, Zhongxing Jiang, Feng Guo

    Identifying new prognostic biomarkers and selecting treatment regimens based on them can improve outcomes of adult patients with B-cell acute lymphoblastic leukemia (B-ALL). Extracellular matrix protein 1(ECM1) is a glycoprotein involved in many biologic processes. Here we aimed to determine the expression and the prognostic value of ECM1 in B-ALL. One hundred and six newly-diagnosed B-ALL patients (seventy-one adult patients and thirty-five children patients) were enrolled from March 2013 to December 2018. The ECM1 transcript levels were significantly different among different disease state. Among 71 adult B-ALL patients, ECM1-high group has a higher initial platelet count( p=0.004),more BCR-ABL fusion positive patients (p=0.004) and poor risk patients (p=0.021) than ECM1-low group, whereas no significant relationship with any other clinical characteristics was observed. ECM1-high group had significantly lower 3-year OS (11.4% vs. 36.1%, p=0.015) and 3-year RFS (9.7% vs. 29.4%, p=0.047) compared to ECM1-low group. In the multivariate Cox regression model, high ECM1 expression was an independent adverse prognostic factor for OS(HR=3.0(1.4-6.6), p=0.007). Our data demonstrated that the expression of ECM1 could serve as a novel prognostic biomarker for adult patients with B-ALL.

  • Open Access

    LncRNA CRNDE Promotes the Progression of B-cell Precursor Acute Lymphoblastic Leukemia by Targeting the miR-345-5p/CREB Axis

    by Weimin Wang, Feifei Wu, Ping Ma, Silin Gan, Xue Li, Li Chen, Ling Sun, Hui Sun, Zhongxing Jiang, Feng Guo

    The imbalance between the proliferation and apoptosis of B-cell precursors is an important contributor to the pathogenesis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), while its specific regulatory mechanism remains perplexing. This study aimed to expound the underlying mechanism of the proliferation and apoptosis of BCP-ALL cells from the perspective of non-coding RNA. In this study, long non-coding RNA colorectal neoplasia differentially expressed (LncRNA CRNDE) was upregulated in the bone marrow of BCP-ALL patients and BCP-ALL cell lines (NALM-6 and RS4;11). Functionally, LncRNA CRNDE knockdown restrained cell proliferation and boosted cell apoptosis in NALM-6 and RS4;11 cells. The subsequent investigation confirmed that LncRNA CRNDE bound to miR-345-5p and negatively regulated miR-345-5p expression. The overexpression of miR-345-5p suppressed cell proliferation and boosted cell apoptosis in NALM-6 and RS4;11 cells. Further experiments revealed that miR345-5p downregulated cyclic AMP response element binding protein (CREB) expression by targeting its mRNA directly. CREB overexpression reversed the effect of miR345-5p mimic on cell proliferation and apoptosis in NALM6 and RS4;11 cells. Finally, in vivo experiments showed that LncRNA CRNDE knockdown prolonged the survival of mice xenotransplanted with NALM-6 cells. In conclusion, LncRNA CRNDE upregulated CREB expression by suppressing miR345-5p, thus promoting cell proliferation and reducing cell apoptosis in BCP-ALL.


  • Open Access

    Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort

    by Rui Jia, Stephanie Shepheard, Jiaoting Jin, Fangfang Hu, Xing Zhao, Li Xue, Li Xiang, Huaguang Qi, Qiumin Qu, Feng Guo, et al.

    To comprehensively assess whether p75ECD in urine could be a candidate biomarker for ALS evaluation. Urine samples were collected from 101 ALS patients, 108 patients with other neurological disease (OND) and 97 healthy controls. 61 ALS patients were followed up with clinical data including ALSFRS-r every 6 to 12 months, 23 ALS patients died and 17 ALS patients lost touch during follow up period. Enzyme-linked immunoassay was employed to determine urine p75ECD concentration. The ALSFRS-r was employed to assess the severity of ALS. The concentration of p75ECD in ALS was significantly higher than that of OND and CTRL (p < 0.001). Additionally, urine p75ECD concentrations in ALS-definite grade patients were significantly higher than that in ALS-probable grade and ALS-possible grade patients (p < 0.001). Higher urine p75ECD concentrations were correlated with increased clinical stage (p = 0.0309); urine p75ECD concentrations and ALSFRS-r were negatively correlated (p = 0.022); and urine p75ECD concentration in the fast-progressing ALS group was significantly higher than that in slow-progression (p = 0.0026). Our finding indicates that urine p75ECD concentration provides additional evidence for patients with clinically suspected ALS, and can be employed to evaluate ALS-severity.


  • Open Access

    Overexpression of the FoxO1 Ameliorates Mesangial Cell Dysfunction in Male Diabetic Rats

    by Guijun Qin, Yingni Zhou, Feng Guo, Lei Ren, Lina Wu, Yuanyuan Zhang, Xiaojun Ma, Qingzhu Wang

    The dysfunction of mesangial cells (MCs) in high-glucose (HG) conditions plays pivotal role in inducing glomerular sclerosis by causing the imbalance between generation and degradation of extracellular matrix (ECM) proteins, which ultimately leads to diabetic nephropathy. This study was designed to determine the function of forkhead box protein O1 (FoxO1), an important transcription factors in regulating cell metabolism and oxidative stress, in MCs in HG conditions. Up-regulation of fibronectin, collagen type IV, and plasminogen activator inhibitor (PAI-1) was observed under HG conditions in vivo and in vitro, accompanied with elevation of protein kinase B (Akt) phosphorylation and reduction of FoxO1 bioactivity. After overexpression of constitutively active (CA) FoxO1 in vivo and in vitro by using lentivirus vector, in vivo and in vitro, FoxO1 expression and activity was increased, in accordance with up-regulation of antioxidative genes (catalase and superoxide dismutase, leading to alleviated oxidative stress as well as attenuated Akt activity, whereas overexpression of wild type-FoxO1 only expressed partial effect. Moreover, CA-FoxO1 decreased the expression of fibronectin, collagen type IV, and PAI-1, causing amelioration of renal pathological changes and decrease of ECM protein deposition in glomerulus. Overexpression of CA-FoxO1 in renal cortex also decreased activin type-I receptor-like kinase-5 levels and increased signaling mothers against decapentaplegic (Smad) 7 levels, and simultaneously inhibited Smad3 phosphorylation. Results from in vitro study indicated that increased combination of FoxO1 and Smad3 may interfere with the function of Smad3, including Smad3 phosphorylation and translocation, interaction with cAMP response element binding protein (CREB)-binding protein, and binding with PAI-1 promoter. Together, our findings shed light on the novel function of FoxO1 in inhibiting ECM deposition, which is beneficial to ameliorate MC dysfunction.